POSACONAZOLE — NEW AZOLE BROAD-SPECTRUM ANTIFUNGAL AGENT FOR PREVENTION AND TREATMENT OF INVASIVE MYCOSES
Abstract
Key words: mycoses, posaconazole, treatment.
About the Author
N.N. KlimkoRussian Federation
References
1. Clark T.A, Hajjeh R.A. Recent trends in the epidemiology of invasive mycoses. Curr. Opin. Infect. Dis. 2002; 15: 569–574.
2. Hayes-Lattin B, Maziarz RT. Update in the epidemiology, prophylaxis, and treatment of fungal infections in patients with hematologic disorders. Leuk Lymphoma. 2004; 45: 669–680.
3. Климко Н.Н., Веселов А.В. Новые препараты для лечения инвазивных микозов. Клиническая микробиология, антимикробная химиотерапия. 2003; 5: 342–353.
4. Dodds Ashley E., Alexander B. Posaconazole. Drugs Today. 2005; 41 (6): 393–400.
5. НОКСАФИЛ. Инструкция по медицинскому применению препарата. 2007.
6. Groll A., Walsh T. Posaconazole: clinical pharmacology and potential for management of fungal infections. Expert. Rev. Anti Infect. Ther. 2005; 3 (4): 467–487.
7. Boucher H., Groll A., Chiou C. et al. Newer systemic antifungal agents: pharmacokinetics, safety and efficacy. Drugs. 2004; 64 (18): 1997–2020.
8. Andes D., Marchillo K., Conklin R. et al. Pharmacodynamics of a new triazole, posaconazole, in a murine model of disseminated candidiasis. Antimicrob Agents Chemother. 2004; 48 (1): 137–142.
9. Pfaller M., Messer S., Hollis R. et al. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000. Antimicrob Agents Chemother. 2002; 46 (4): 1032–1037.
10. Sabatelli F., Patel R., Mann P. et al. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob Agents Chemother. 2006; 50 (6): 2009–2015.
11. Torres-Narbona M., Guinea J., Martinez-Alarcon J. et al. In vitro activities of amphotericin B, caspofungin, itraconazole, posaconazole, and voriconazole against 45 clinical isolates of zygomycetes: comparison of CLSI M38–A, Sensititre Yeast One, and the Etest. Antimicrob. Agents Chemother. 2007; 51 (3): 1126–1129.
12. Torres H., Hachem R., Chemaly R. et al. Posaconazole: a broad-spectrum triazole antifungal. Lancet Infect. Dis. 2005; 12: 775–785.
13. Antachopoulos C., Walsh T. New agents for invasive mycoses in children. Curr. Opin. Pediatr. 2005; 17 (1): 78–87.
14. Barchiesi F., Spreghini E., Santinelli A. et al. Posaconazole prophylaxis in experimental systemic zygomycosis. Antimicrob Agents Chemother. 2007; 51 (1): 73–77.
15. Courtney R., Pai S., Laughlin M. et al. Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults. Antimicrob. Agents Chemother. 2003; 47 (9): 2788–2795.
16. Krieter P., Flannery B., Musick T. et al. Disposition of posaconazole following single dose oral administration in healthy subjects. Antimicrob. Agents Chemother. 2004; 48 (9): 3543–3551.
17. Ullmann A., Cornely O., Burchardt A. et al. Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection. Antimicrob. Agents Chemother. 2006; 50 (2): 658–666.
18. Conte J.R., Golden J.A., Krishna G. et al. Intra pulmonary ppharmacokinetics-pharmacodynamics of posaconazole. 3 Advancer Against Aspergillosis. 2008.
19. Wexler D., Courtney R., Richards W. et al. Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study. Eur. J. Pharm. Sci. 2004; 21 (5): 645-653.
20. Sansone-Parsons A., Krishna G., Simon J. et al. Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers. Antimicrob. Agents Chemother. 2007; 51 (2): 495–502.
21. Naggapan V., Deresinski S. Posaconazole: a broad-spectrum triazole antifungal agent. Clin. Infect Dis. 2007; 45: 1610–1617.
22. Krishna G., Sansone–Parsons A., Martinho M. et al. Posaconazole plasma concentrations in juvenile patients with invasive fungal infection. Antimicrob. Agents Chemother. 2007; 51 (3): 812–818.
23. Ullmann A., Cornely O. Antifungal prophylaxis for invasive mycoses in high risk patients. Curr. Opin. Infect. Dis. 2006; 19 (6): 571–576.
24. Cornely O., Maertens J., Winston D. et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N. Engl. J. Med. 2007; 356 (4): 348–359.
25. Ullmann A., Lipton J., Vesole D. et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N. Engl. J. Med. 2007; 356 (4): 335–347.
26. Keating G. Posaconazole. Drugs. 2005; 65 (11): 1553–1567.
27. Pitisuttithum P., Negroni R., Graybill J. et al. Activity of posaconazole in the treatment of central nervous system fungal infections. J. Antimicrob. Chemother. 2005; 56 (4): 745–755.
28. Walsh T., Raad I., Patterson T. et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. CID. 2007; 44 (1): 2–12.
29. Tobon A., Arango M., Fernandez D. et al. Mucormycosis (zygomycosis) in a heart-kidney transplant recipient: recovery after posaconazole therapy. CID. 2003; 36 (11): 1488–1491.
30. Greenberg R., Mullane K., van Burik J. et al. Posaconazole as salvage therapy for Zygomycosis. Antimicrob. Agents Chemother. 2006; 50 (1): 126–133.
31. Van Burik J., Hare R., Solomon H. et al. Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. CID. 2006; 42 (7): 61–65.
32. Rutar T., Cockerham K. Periorbital zygomycosis (mucormycosis) treated with posaconazole. Am. J. Ophthalmol. 2006; 142 (1): 187–188.
33. Page R., Schwiesow J. Hilts A. Posaconazole as salvage therapy in a patient with disseminated zygomycosis: case report and review of the literature. Pharmacotherapy. 2007; 27 (2): 290–298.
34. Raad I., Hachem R., Herbrecht R. et al. Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions. CID. 2006; 42 (10): 1398–1403.
35. Tu E., McCartney D., Beatty R. et al. Successful Treatment of Resistant Ocular Fusariosis With Posaconazole (SCH-56592). Am. J. Ophthalmol. 2007; 143 (2): 222–227.
36. Restrepo A., Tobon A., Clark B. et al. Salvage treatment of histoplasmosis with posaconazole. J. Infect. 2007; 54 (4): 319–327.
37. Notheis G., Tarani L., Costantino F. et al. Posaconazole for treatment of refractory invasive fungal disease. Mycoses. 2006; 1: 37–41.
38. De Decker K., Van Poucke S., Wojciechowski M. et al. Successful use of posaconazole in a pediatric case of fungal necrotizing fasciitis. Pediatr. Crit Care Med. 2006; 7 (5): 482–485.
39. Sorensen J., Becker M., Porto L. et al. Rhinocerebral zygomycosis in a young girl undergoing allogeneic stem cell transplantation for severe aplastic anaemia. Mycoses. 2006; 49: 31–36.
40. Chan Y., Goldwater P., Saxon B. Successful treatment of cutaneous and subcutaneous zygomycosis in an immunosuppressed patient with aplastic anaemia. J. Paediatr. Child Health. 2007; 43 (1–2): 87–89.
41. Raad I., Graybill J., Bustamante A. et al. Safety of long term oral posaconazole use in the treatment of refractory invasive fungal infections. CID. 2006; 42 (12): 1726–1734.
42. Walsh T.J., Anaissie E.J., Denning D.W. et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Disieases Society of America. Clin. Infect. Dis. 2008; 46: 327–360.
43. NCCN Clinical Practice Guidelines in Oncology. 2007. V.1. Prevention and Treatment of Cancer Related Infections. www.nccn.org.
44. Maertens J.A., Frèreb P., Lass-Flör C. et al. Primary antifungal prophylaxis in leukemia patients. Eur. J. Cancer. 2007; 5: 43–49.
Review
For citations:
Klimko N. POSACONAZOLE — NEW AZOLE BROAD-SPECTRUM ANTIFUNGAL AGENT FOR PREVENTION AND TREATMENT OF INVASIVE MYCOSES. Current Pediatrics. 2008;7(2):93-100.
Email this article 
